Year: 2023

Selecta Biosciences Announces Merger with Cartesian Therapeutics

Written by Customer Service on November 13, 2023. Posted in Mergers And Acquisitions.

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 development of Descartes-08 for MG – – Combined company to be led by Carsten Brunn, Ph.D.; Cartesian Co-Founders Murat Kalayoglu, M.D., Ph.D., and Michael Singer,...

Hour Loop Reports Third Quarter 2023 Results

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Demonstrates Strong Revenue Growth Despite Challenging e-Commerce Environment Increases Full Year 2023 Revenue Guidance REDMOND, Wash., Nov. 13, 2023 (GLOBE NEWSWIRE) — Hour Loop, Inc. (NASDAQ: HOUR) (“Hour Loop”), a leading online retailer, announces its financial and operational results for the quarter ended September 30, 2023. Financial Highlights for Third Quarter 2023:Net revenues increased 66.1% to $29.2 million, compared to $17.6 million in the year-ago period; Net loss totaled $0.02 million, compared to net income $0.15 million in the year-ago period; and Cash used for operating activities was $3.8 million and $14.5 million for the nine months ended September 30, 2023 and 2022, respectively.Management Commentary “We are pleased to report our third quarter 2023 results, in which we continued to deliver significant revenue...

Bitcoin Depot Reports Third Quarter 2023 Financial Results

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Revenue of $179.5 Million, Up 3% Year-over-Year Net Income of $1.1 Million, Down 68% Year-over-Year Adjusted EBITDA (non-GAAP) of $13.9 Million, Up 21% Year-over-Year Reiterates Full Year 2023 Guidance for Revenue and Adjusted EBITDA ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the third quarter ended September 30, 2023. Bitcoin Depot will host a conference call and webcast at 11:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Our results this quarter continue to demonstrate the strength of our business model and how we’re able to deliver strong results irrespective of the market environment or price of Bitcoin,”...

Xcel Brands Announces License with ALPHA OES for Longaberger

Written by Customer Service on November 13, 2023. Posted in Public Companies.

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with billions of dollars in retail sales generated by its brands through social commerce and live-stream shopping, today announced a new licensing agreement with ALPHA OES, a provider of eCommerce services and strategies for brands. Under the terms of the licensing agreement, ALPHA OES will take over the day-to-day operations for Xcel’s Longaberger eCommerce business. “We’re excited to partner with ALPHA OES on the Longaberger brand,” said Robert W. D’Loren, Chairman and CEO of Xcel Brands. “Since we acquired Longaberger in 2019, we’ve been able to evolve the business from a direct sales company into a social commerce marketplace for home products featuring Longaberger’s American made baskets....

Red Cat CEO to Speak at the Partnership for Drone Competitiveness’ Launch Commemoration Outside the U.S. Capitol

Written by Customer Service on November 13, 2023. Posted in Public Companies.

Jeff Thompson to join the Association for Uncrewed Vehicle Systems International, industry leaders, and members of Congress during November 14th press conference SAN JUAN, Puerto Rico, Nov. 13, 2023 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a drone technology company integrating robotic hardware and software for military, government and commercial operations, announces CEO Jeff Thompson will be a featured speaker at the Association for Uncrewed Vehicle Systems International’s Partnership for Drone Competitiveness press conference to be held in Washington, D.C. at 1pm ET on November 14, 2023. The event commemorates the recent launch of the alliance at the House Triangle outside of the Capitol and will feature leading U.S. drone companies and members of Congress. The Partnership for Drone...

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Written by Customer Service on November 13, 2023. Posted in Public Companies.

The thyroid hormone receptor-beta (THR-b) drug ALG-055009:Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects Demonstrated favorable PK with low variability Dose responsively lowered lipid levels in study subjects Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent Has a favorable overall risk-benefit profile which supports conducting a 12-week Phase 2a study in NASH subjectsSOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced...

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

Written by Customer Service on November 13, 2023. Posted in Public Companies.

SAINT LAURENT, Quebec, Nov. 13, 2023 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”) wishes to remind its shareholders of record as of October 2, 2023 (the “Shareholders”) of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 (the “Special Meeting”) as a virtual meeting only. At the Special Meeting, Shareholders will be asked to vote:to amend the certificate of incorporation of the Company to increase the authorized common stock from 450,000,000 shares of common stock (the “Shares”) to 580,000,000 Shares; to approve (the “Pricing Shareholder Approval”) for purposes of complying with Sections 607(e) and 607(i) of the Toronto Stock Exchange (“TSX”) Company Manual, the issuance of Shares...

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

Written by Customer Service on November 13, 2023. Posted in Public Companies.

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the treatment of uveal melanoma (UM) metastatic to the liver (mUM) (NCT00986661). mUM patients enrolled in this study received 1 or more cycles of PV-10 injection into 1 or more hepatic metastases. Where indicated, standard of care immune checkpoint blockade (CB), as either monotherapy pembrolizumab or the combination of ipilimumab and nivolumab (IN), was also administered. To date, 25 mUM patients have received monotherapy PV-10 or PV-10 in combination with CB:Median age 64.3 years, range 32-80, 14 male (56%), 11 female (44%), 17 Stage M1a (68%), 7 M1b (28%), 1 M1c (4%), Median of 1 line of prior therapy for metastatic...

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs. Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer. Alzheimer’s Disease (AD):Completed enrollment in the randomized, double-blind, Phase 1b/2a SIGNAL-AD...

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023 Enrollment of 120 patients in Phase 3 registrational trial of denifanstat in recurrent glioblastoma (GBM) announced by license partner, Ascletis Presentation of positive topline Phase 2 denifanstat monotherapy data from Ascletis’ acne program SAN MATEO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today reported financial results for the third quarter ended September...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals